Aftershocks of cancer chemotherapy: Managing adverse effects

Journal of the American Animal Hospital Association

Volumn 43, Issue 1, 2007, Pages 1-7

  Thamm, Douglas H ^a   Vail, David M ^b  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 33947187195     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0430001     Document Type: Article

References (29)

1. Chun R, Garrett L, MacEwen EG. Cancer chemotherapy. In: Small Animal Clinical Oncology. 3rd ed. Philadelphia: Saunders, 2001: 92-118.
2. Bronden LB, Rutteman GR, Flagstad A, et al. Study of dog and cat owners' perceptions of medical treatment for cancer. Vet Rec 2003;152:77-80.
3. Mellanby RJ, Herrtage ME, Dobson JM. Owners' assessments of their dog's quality of life during palliative chemotherapy for lymphoma. J Small Anim Pract 2003;44:100-103.
4. Group VCO. Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Compar Oncol 2004;2:194-213.
5. Polsky B, Armstrong D. Infectious complications of neoplastic disease. Am J Infect Control 1985;13:199-209.
6. Savage DC. Introduction to mechanisms of association of indigenous microbes. Am J Clin Nutr 1979;32:113-118.
7. Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 1972;77:707-714.
8. Fan TM, Kitchell BE, Dhaliwal RS, et al. Hematological toxicity and therapeutic efficacy of lomustine in 20 tumor-bearing cats: critical assessment of a practical dosing regimen. J Am Anim Hosp Assoc 2002;38:357-363.
9. Moore AS, London CA, Wood CA, et al. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med 1999;13:395-398.
10. Rassnick KM, Gieger TL, Williams LE, et al. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats. J Vet Intern Med 2001;15:196-199.
11. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-605.
12. Page RL, McEntee MC, George SL, et al. Pharmacokinetic and phase I evaluation of carboplatin in dogs. J Vet Intern Med 1993;7:235-240.
13. Kisseberth WC, MacEwen EG. Complications of cancer and its treatment. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology. 3rd ed. Philadelphia: Saunders, 2001:198-232.
14. Navigante AH, Cerchietti LC, Costantini P, et al. Conventional chest radiography in the initial assessment of adult cancer patients with fever and neutropenia. Cancer Control 2002;9:346-351.
15. Renoult E, Buteau C, Turgeon N, et al. Is routine chest radiography necessary for the initial evaluation of fever in neutropenic children with cancer? Pediatr Blood Cancer 2004;43:224-228.
16. van de Wetering MD, de Witte MA, Kremer LC, et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer 2005;41:1372-1382.
17. Waaij D. The colonization resistance of the digestive tract in experimental animals and its consequences for infection prevention, acquisition of new bacteria and the prevention of spread of bacteria between cage mates. In: Waaij D, Verhoef J, eds. New criteria for antimicrobial therapy: maintenance of digestive tract colonization resistance. Excerpta Medica International Congress Series. Amsterdam: Elsevier, 1979:43-53.
18. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002;10:181-188.
19. Ogilvie GK. Dolasetron: a new option for nausea and vomiting. J Am Anim Hosp Assoc 2000;36:481-483.
20. Hall JA, Washabau RJ. Gastrointestinal prokinetic therapy: acetylcholinesterase inhibitors. Comp Cont Ed Pract Vet 1997;19:615-620.
21. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res 2000;6:3680-3686.
22. Bertelli G, Gozza A, Forno GB, et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995;13:2851-2855.
23. Spugnini EP. Use of hyaluronidase for the treatment of extravasation of chemotherapeutic agents in six dogs. J Am Vet Med Assoc 2002;221:1419,1420,1437-1440.
24. Poirier VJ, Hershey AE, Burgess KE, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004;18:219-222.
25. Hugnet C, Bentjen SA, Mealey KL. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France. J Vet Pharmacol Ther 2004;27:227-229.
26. Mealey KL. Therapeutic implications of the MDR-1 gene. J Vet Pharmacol Ther 2004;27:257-264.
27. Mealey KL, Munyard KA, Bentjen SA. Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of herding breed dogs living in Australia. Vet Parasitol 2005;131: 193-196.
28. Mealey KL, Northrup NC, Bentjen SA. Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity. J Am Vet Med Assoc 2003;223:1434, 1453-1455.
29. Neff MW, Robertson KR, Wong AK, et al. Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage. Proc Natl Acad Sci U S A 2004;101:11725-11730.